Publications by authors named "B Hoggart"
Background: A lack of objective outcome measures and overreliance on subjective pain reports in early proof-of-concept studies contribute to the high attrition of potentially effective new analgesics. We studied the utility of neuroimaging in providing objective evidence of neural activity related to drug modulation or a placebo effect in a double-blind, randomized, placebo-controlled, three-way crossover trial.
Methods: We chronically administered pregabalin or tramadol (first-line and second-line analgesics, respectively), recommended for neuropathic pain, in 16 post-traumatic neuropathic pain patients.
Can skin disease cause neuropathic pain? A study in pachyonychia congenita.
Clin Exp Dermatol
January 2016
Introduction: Pachyonychia congenita (PC) is a rare skin disorder caused by an autosomal dominant mutation in one of five genes encoding keratin (K6a, K6b, K6c, K16 or K17; each defining one PC subtype). Pain is a prominent symptom, but its severity and type are poorly characterized.
Methods: In total, 35 genotyped US patients with PC consented to clinical assessment including the quality of life (QoL) questionnaire EQ-5D-3L, the Brief Pain Inventory (BPI) and painDETECT.
Peripheral neuropathic pain (PNP) poses a significant clinical challenge. The long-term efficacy of delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) oromucosal spray was investigated in this 38-week open-label extension study. In total, 380 patients with PNP associated with diabetes or allodynia entered this study from two parent randomised, controlled trials.
View Article and Find Full Text PDFArticle Synopsis
- Tapentadol prolonged release has been found effective and well-tolerated for treating moderate-to-severe chronic osteoarthritis pain in previous studies, particularly after other analgesics were discontinued.
- The study aimed to assess tapentadol's effectiveness and tolerability in patients with severe knee pain who switched from WHO step III opioids due to adverse effects.
- Conducted from October 2009 to June 2010, this open-label study focused on patients who had responded to opioid therapy but faced side effects, allowing them to transition directly to tapentadol for pain management over a specified treatment period.